Hematology News Editorial Advisory Board
MATT KALAYCIO, M.D., Cleveland Clinic Taussig Cancer Institute
Dr. Kalaycio chairs the department of hematologic oncology and blood disorders at Cleveland Clinic Taussig Cancer Institute, Cleveland. He holds a joint appointment in the clinic's transplant center and is a professor in the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Board-certified in hematology and medical oncology, Dr. Kalaycio's clinical interests are in leukemia and stem cell transplantation. In addition to his numerous scientific publications, Dr. Kalaycio has edited a book on leukemia and co-edited a book on clinical malignant hematology.
Dr Sosa is an Assistant Professor of Medicine in the section of Hematology and Oncology at Baylor College of Medicine. She received her MD/PhD at the University of Minnesota in Minneapolis and completed her clinical training in internal medicine and hematology at Vanderbilt University. Her research interests are in the field of thrombosis, with a specific emphasis in the role of platelet activation in disease. In collaboration with John Oates’ lab at Vanderbilt, she has developed novel and robust biomarkers to assess platelet activation in vivo in diseases characterized by high risk of thrombosis. She is utilizing these markers of thrombosis to facilitate clinical investigations of human diseases in which platelets are pivotal contributors, with the overall goal of improving the effectiveness of anti-platelet therapy, characterizing platelet dysfunction as an important phenotype for prospective epidemiological studies, and informing the individualization of anti-platelet therapy. Additionally, she is interested in the role of platelet activation in the hematogenous dissemination of tumor cells. She is studying the role of platelet modulation of COX-2 and prostaglandin E2 production by solid tumor adenocarcinomas, with a specific emphasis on the role of aspirin therapy in prevention of metastatic spread.
JEFFREY ALLAN ZONDER, M.D., is Professor in the Departments of Oncology at the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine. He is the leader of the KCI Myeloma Multidisciplinary sub-team, Medical Director for Karmanos Cancer Center Therapeutic Apheresis Unit, a medical advisor for the Amyloidosis Support Group Networks, and a member of the International Myeloma Working Group, the International Myeloma Society and the International Amyloidosis Society. He received his medical degree from Wayne State University School of Medicine. He completed his medical residency at the University of Rochester in Rochester, New York, before returning to Wayne State University for Hematology-Oncology fellowship training. He is a member of the American Society of Hematology, the American Society of Clinical Oncology, the American Medical Association and the SWOG Barlogie-Salmon Myeloma Committee. He was the national principal investigator of the SWOG study S0232, a randomized trial that helped establish the efficacy of lenalidomide and dexamethasone as initial treatment for myeloma. Dr. Zonder has authored or co-authored numerous original research papers, review articles, book chapters, and research abstracts on myeloma and amyloidosis.